Loading...
Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium–glucose cotransporter-2 (SGLT-2) inhibitors, when used individually, each lower risk for adverse cardiorenal outcomes and mortality in patients with diabetes. But the combined effect of these drugs on such outcomes has not been studied extensively.
Using U.K. databases, investigators identified 6700 patients (mean age, 57) with longstanding diabetes who started GLP-1 agonists during an 8-year period and added SGLT-2 inhibitors either at the same time or later. These patients were matched, using propensity scores, with 6700 patients who started GLP-1 agonists and did not add SGLT-2 inhibitors. Similarly, 8900 patients who started SGLT-2 inhibitors and added GLP-1 agonists were match…